Brief: MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
03/12/2024 13:52
Dec 3 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY ANNOUNCES EXPANSION OF CLINICAL SUPPLY
AGREEMENT WITH REGENERON FOR PHASE 2 TRIAL IN NON-SMALL CELL
LUNG CANCER
* MAIA BIOTECHNOLOGY INC - EXPANSION OF 2021 CLINICAL SUPPLY
AGREEMENT FOR PHASE 2 TRIAL
* MAIA BIOTECHNOLOGY INC - EXPECTS NEW PATIENT ENROLLMENT TO
BEGIN
SOON
Source text: ID:nBwSBTZZa
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale